Progress in the Study of the Effect of SGLT2 Inhibitors on Glomerular Filtration Rate and Its Mechanism

钠–葡萄糖共转运蛋白2 (Sodium-Glucose Cotransporter, SGLT) 2抑制剂是一类作用机制独特的新型口服降糖药，在降低跨肾小球压的同时可能导致用药早期肾小球滤过率下降。本文综述了近年来各种钠–葡萄糖转运蛋白2抑制剂对2型糖尿病患者肾小球滤过率影响的相关研究及其作用机制，从而为SGLT2抑制剂在T2DM治疗安全性方面提供新的理念和依据。Sodium-glucose cotransporter (SGLT) 2 inhibitors are a new class of oral hypoglycemic agents with a unique mechanism, which may lead to a decrease in glomerular filtration rate in the early phase of drug administration while lowering transglomerular pressure. In this paper, we review the recent studies on the effects of various sodium-glucose cotransporter 2 inhibitors on glomerular filtration rate in type 2 diabetes mellitus patients and their mechanisms of action, so as to provide new concepts and rationale for the safety of SGLT2 inhibitors in the treatment of T2DM.